Design Therapeutics reports FY2021 net loss $35.5M, IND cleared for DT-216 Phase 1 trial

Design Therapeutics, Inc.

Net loss $35.5M for FY2021 ($11.1M in Q4); cash and investments $384.1M at Dec 31, 2021.
IND for DT-216 (Friedreich Ataxia) cleared by FDA; Phase 1 trial to begin shortly.
Appointed Dr. Jae Kim as Chief Medical Officer to lead clinical development.
Preclinical data on GeneTAC molecules for Fuchs endothelial corneal dystrophy to be presented at ARVO May 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.